With almost two decades of experience, we are one of the leading experts in the provision of radionuclides and radiopharmaceuticals for nuclear medicine and molecular imaging.
We offer individual, valuable and innovative solutions for researchers, healthcare professionals and manufacturers working toward the diagnosis and treatment of different diseases.
Our expertise in radiometals for theranostic purposes empowers us to support ambitious startups and established institutions alike.
As a leading supplier in nuclear medicine, we offer a wide range of high-quality radiopharmaceuticals and radiochemicals for use in research and clinical applications.
This includes but is not limited to Ge-68/Ga-68 generators, Yttrium-90 and Lutetium-177, produced at our GMP manufacturing sites in Germany, the USA and in the future at our planned site in China.
We are experienced in providing support for projects in early development and pre-clinical stages.
Based on specified biomolecules and radioisotopes we develop a robust radioconjugate and optimize it and the methods for manufacturing and testing it to define potential radiopharmaceuticals.
The result is a comprehensive report as a basis for further development and clinical stages.
We serve as an expert in the clinical and commercial supply for projects using alpha, beta or gamma radiation.
Whether you require radionuclides in highest quality, radiolabeled pharmaceuticals or a partner to support you with GLP and cGMP-compliant production infrastructure, our experienced, international teams will provide the ideal solution tailored to your needs.
We offer companies without the necessary infrastructure the possibility to rent equipped space and experienced personnel for the completion of testing and project milestones. Our clean rooms will be equipped according to your requirements with hot cells, radiosynthesis, quality control and further equipment. Our experienced teams will be consulted to guarantee optimal surroundings for your work.
We are manufacturing partner for clinical supply of Bayer’s innovative Targeted Thorium Conjugates (TTCs) in Europe. TTCs are a next-generation targeted alpha therapy using the alpha-emitter Thorium-227. We are providing infrastructure for handling, manufacture and distribution of the TTCs for the purpose of clinical trial in Europe.
Octreopharm Sciences (OPS) is an innovative company developing compounds for NET management. Prior to acquisition by Ipsen in 2015, we invested in OPS, provided laboratory space as well as equipment and helped expedite the development of their product. In the future, we will continue cooperation, by supporting OPS as a contract manufacturer.
Curasight is a pioneer working on the exploitation of the novel PET imaging target uPAR for improved diagnosis of various types of cancer. Eckert & Ziegler provides qualified personnel, laboratory space and equipment to get the uPAR PET ligand ready for the market as quickly as possible, executing experimental work and regulatory preparation.
Sirtex is the manufacturer of SIR-Spheres® Y-90 resin microspheres, a medical device used in Selective Internal Radiation Therapy (SIRT) of liver cancer. We are in a long-term supply agreement for the use of our Yttrium-90 in SIR-Spheres®, supplying Sirtex’s sites in Frankfurt, Boston and Singapore as a reliable partner.